[Artificial heart in terminal stage of dilated cardiomyopathy in childhood]

B Stiller1, I Dähnert, F Berger

  • 1Abteilung für angeborene Herzfehler Kinderkardiologie Deutsches Herzzentrum Augustenburger Platz 1 D-13353 Berlin. stiller@dhzb.de

Zeitschrift Fur Kardiologie
|January 10, 2001
PubMed

Insights

Pediatric dilated cardiomyopathy can be fatal. A miniaturized ventricular assist device successfully bridged 12 of 15 children to heart transplantation, improving outcomes for critically ill pediatric patients.

Area of Science:

  • Pediatric Cardiology
  • Mechanical Circulatory Support
  • Congenital Heart Disease

Context:

  • Dilated cardiomyopathy in children can rapidly progress to fatal outcomes.
  • Intensive medical therapy often fails in pediatric patients with end-stage heart failure.
  • Urgent need for effective bridging strategies to cardiac transplantation in pediatric populations.

Purpose:

  • To evaluate the efficacy of a miniaturized pulsatile ventricular assist device (Berlin Heart) as a bridge to cardiac transplantation in pediatric patients.
  • To assess the safety and outcomes associated with mechanical circulatory support in children with end-stage heart failure.

Summary:

  • Fifteen children (4 months–15 years) with severe dilated cardiomyopathy and multiorgan failure received a miniaturized biventricular assist device.
  • Twelve of 15 children were successfully bridged to transplantation, with support durations ranging from 1 to 98 days (mean 24 days).
  • Complications included hemorrhage, sepsis, pulmonary failure, and one cerebral infarction; seven transplanted children remain in good condition.

Impact:

  • Demonstrates the feasibility and effectiveness of ventricular assist devices in pediatric patients, including infants.
  • Offers a viable mechanical circulatory support solution for critically ill children awaiting heart transplantation.
  • Highlights the potential to improve survival rates in pediatric patients with end-stage heart failure.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...